, the estimated goodwill may be subject to further adjustments depending on the determination of fair value, which is expected to be finalized within Q2/2019 and it is to be amortized over the estimated
/2020 Operating Results Overall operating results of the Company and its subsidiaries (unit: THB million) Q3/19 Q2/20 Q3/20 change +/(-) 9M/19 9M/20 Change +/(-) YoYYoY QoQ Operating revenue 19,227 18,138
from sale. Besides, other income also increased from the revenue of by products, waste and material Information of the 2nd Quarter Consolidated Separate 3 months Change 3 months Change 2017 2016 Amount
www.interpharma.co.th IP_OCS/011/2020 8th June 2020 Subject: Notify the Resolutions of the Board of Directors Meeting, Change of Objectives of Funds Usage, Acquisition of Assets, The Issuance of Debentures and Fix the
persons); therefore, it no longer has control in the company, resulting in the change of MACO’s status from a subsidiary to an associate company of VGI. After the restructuring, MACO will focus on
, in all cases, the accuracy and completeness of such data, particularly those from outside the company. In addition, any forward looking statements are subject to change as market conditions and actual
Revenues Consolidated financial statements (Thousands Baht) Nine-month Change 3nd Quarter Change 2562 2561 Amount % 2562 2561 Amount % Revenue from sales 1,727,237 1,168,546 558,691 47.81% 659,160 427,881
. Revenues (Thousands Baht) Year Change 4th Quarter Change Amount % Amount % Revenue from sales 1,566,147 1,477,687 88,461 5.99% 437,506 371,485 66,021 17.77% Other income 19,457 14,472 4,985 34.45% 6,968
Revenues Consolidated (Thousands Baht) Year Change 4th Quarter Change 2018 2017 Amount % 2018 2017 Amount % Revenue from sales 1,540,078 1,566,147 -26,069 -1.66% 371,532 437,506 -65,974 -15.08% Other income
Revenues Consolidated financial statements (Thousands Baht) Six-month Change 2nd Quarter Change 2562 2561 Amount % 2562 2561 Amount % Revenue from sales 1,068,077 740,665 327,412 44.21% 512,616 372,742